Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 371

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 371
---
reed budgets. Grant income in 2023 also included a grant of €6.1million from the National Institute for Health and Disability Insurance (2024: nil, 2022: nil). This grant aimed to incentivize innovative Belgian biotech companies who are performing research and development activities in order to identify new medicines.

R& D incentives income was primarily composed of:

                                                                                              Year ended December 31,                                                    
                                                                                              2024                                                                       
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                                                                           (Euro, in thousands)                          
  Income from innovation incentive system in France                                           €                                           2,056       5,881      11,075  
  Income from Belgian R& D incentives                                                                                                    16,943      16,535      10,339  
  Tax rebates on payroll withholding taxes of R& D personnel (Belgium & the Netherlands)                                                  8,224      10,552       7,689  
  Total R& D incentives income                                                                €                                          27,223      32,968      29,104  

F-37

Table of Contents

9. Staff costs

Thetablebelowsummarizesthenumberofemployeesofour continuingoperationson December 31, 2024, 2023 and 2022:

                                          2024               2023               2022           
  Number of employees on December 31                704                646                724  
 ───────────────────────────────────────────────────────────────────────────────────────────────
  Total                                             704                646                724  

The average number of FTE’s of our continuing operations during the years2024,2023 and 2022 was:

                                          Year ended December 31,                             
                                                             2024                             
 ──────────────────────────────────────────────────────────────────────────────────────────────
  Members of the Executive Committee                                     4        4        4  
  Research and development                                             408      372      434  
  Commercial and medical affairs                                        26       13        7  
  Corporate and support                                                207      245      250  
  Total                                                                645      634      695  

Their aggregate remuneration comprised:

                                                 Year ended December 31,                                                            
                                                 2024                                                                               
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                              (Euro